SC0062   Click here for help

GtoPdb Ligand ID: 13748

Synonyms: SC-0062 | WX-013 | WX013
Compound class: Synthetic organic
Comment: SC0062 is a small molecule, orally bioactive endothelin receptor A (ETA; EDNRA) antagonist. It is one of the claims in patent WO2020233694 [3]. The code name SC0062 is directly linked to the structure in EP3851435B1 [1].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 13
Hydrogen bond donors 2
Rotatable bonds 12
Topological polar surface area 162.17
Molecular weight 569.39
XLogP -1.04
No. Lipinski's rules broken 3

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES COCCNS(=O)(=O)NC1=NC=NC(=C1C2=CC=C3C(=C2)OCO3)OCCOC4=NC=C(C=N4)Br
Isomeric SMILES COCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC4=C(C=C3)OCO4
InChI InChI=1S/C20H21BrN6O7S/c1-30-5-4-26-35(28,29)27-18-17(13-2-3-15-16(8-13)34-12-33-15)19(25-11-24-18)31-6-7-32-20-22-9-14(21)10-23-20/h2-3,8-11,26H,4-7,12H2,1H3,(H,24,25,27)
InChI Key CJPSPQBOXPPXMN-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
References
1. He K, Gao X, Liu C, Zhang Z, Li X, Li C, Luo Y, Lei M, Li J, Wang Y. (2023)
Medical application of pyrimidine sulfonamides derivatives.
Patent number: EP3851435B1. Assignee: Chinese PLA General Hospital, Shijiazhuang Sagacity New Drug Development Co Ltd. Priority date: 05/06/2019. Publication date: 09/08/2023.
2. Heerspink HJL, Du X, Xu Y, Zhang Y, Liu B, Bi G, Xu C, Luo Q, Wu H, Wan J et al.. (2024)
The Selective Endothelin Receptor Antagonist SC0062 in IgA Nephropathy: A Randomized Double-Blind Placebo-Controlled Clinical Trial.
J Am Soc Nephrol, [Epub ahead of print]. [PMID:39462310]
3. Li J, Lei M, Luo Y. (2020)
Crystal form of pyrimidine sulfonamide compound and preparation method therefor.
Patent number: WO2020233694. Assignee: Shijiazhuang Zhikang Hongren New Drug Development Co., Ltd.. Priority date: 22/05/2020. Publication date: 26/11/2020.
4. Liu Y, Wang W, Qian H, Gui Y, Wang Y, Song R, Chen Q, Rowinsky E, Wang S, Liang X et al.. (2024)
Safety, pharmacokinetics, and pharmacodynamics in healthy Chinese volunteers treated with SC0062, a highly selective endothelin-A receptor antagonist.
Clin Transl Sci, 17 (3): e13750. [PMID:38451110]
5. Luo Y, Lei M, Li J, Xu Y, Wei R, Chen S. (2020)
Pyrimidine sulfamide derivative and preparation method and medical application thereof.
Patent number: EP3719013A1. Assignee: Shijiazhuang Sagacity New Drug Development Co Ltd; Wuxi Biocity Biopharmaceutics Co Ltd. Priority date: 19/11/2018. Publication date: 07/10/2020.